Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations : SABINA Findings From Europe and North America
-
Quint, Jennifer K. (Imperial College London)
;
Arnetorp, Sofie (Payer Analytics. AstraZeneca) ;
Kocks, Janwillem W.H. (University Medical Center Groningen) ;
Kupczyk, Maciej (Karolinska Institutet (Estocolm, Suècia)) ;
Nuevo, Javier (Evidence Generation. AstraZeneca) ;
Plaza, Vicente (Institut d'Investigació Biomèdica Sant Pau) ;
Cabrera, Claudia (BioPharmaceuticals Medical (Evidence). AstraZeneca) ;
Raherison-Semjen, Chantal (Bordeaux University) ;
Walker, Brandie (University of Calgary) ;
Penz, Erika (University of Saskatchewan) ;
Gilbert, Ileen (Medical Affairs. AstraZeneca) ;
Lugogo, Njira Lucia (University of Michigan) ;
van der Valk, Ralf J.P. (Medical Affairs. AstraZeneca) ;
Fong, Andrew ;
Qian, Christina ;
Fabry-Vendrand, Caroline ;
Touboul, Chantal ;
Brzostek, Dorota ;
Maslova, Ekaterina ;
Surmont, Filip ;
Goike, Helena ;
Gandhi, Hitesh ;
Korevaar, J.C. ;
Tkacz, Joseph ;
Johnston, Karissa ;
Peres da Costa, Keith ;
van Dijk, L. ;
Vervloet, M. ;
Pollack, Michael ;
Hernandez, Paul ;
Boarino, S. ;
Noorduyn, Stephen G. ;
Beekman-Hendricks, Wendy ;
Weesie, Y.M. ;
Universitat Autònoma de Barcelona
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
